The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Exercise, Weight Loss, and Breast Cancer Risk: The Importance of BMI

Cleveland Clinic Taussig Cancer Institute

A. Guthrie

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Weightloss in Menopause

Susan Brian

Tirzepatide Updates

Diana Isaacs

Mounjaro Update 2024

Susan Brian

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Tirzepatide for Type 2 Diabetes

Diana Isaacs